ClinicalTrials.gg
DrugBiological

Ciltacabtagene autoleucel clinical trials

Also written JNJ-68284528.

studies test it
10
open now
3
in phase 3
1
first study started
2018

How each study uses ciltacabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ciltacabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Feb 2022 · Carvykti · BLA 125746 (FDA, Purple Book)
European Union
25 May 2022 · Carvykti · EMEA/H/C/005095 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cilta-cel
5
Ciltacabtagene Autoleucel
4

Development codes

JNJ-68284528
4

Studies by the year they started

10 studies that test it; most in 2019 (2)

Studies that test ciltacabtagene autoleucel, by start year
YearStudies
20181
20192
20201
20222
20231
20242
20251

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 3

Janssen Research & Development, LLC (5) · Dana-Farber Cancer Institute (1) · Janssen Scientific Affairs, LLC (1) · Washington University School of Medicine (1) · Medical College of Wisconsin (1) · Nanjing Legend Biotech Co. (1)

Often tested with

Tested in the same studies.

Bortezomib (2) · Dexamethasone (2) · Daratumumab (2) · Talquetamab (2) · Cyclophosphamide (2) · Pomalidomide (1) · Lenalidomide (1) · Fludarabine phosphate (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test ciltacabtagene autoleucel.

Studies

Open first, then newest update. How each study uses ciltacabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 10

Given beside what is tested · 5 — ciltacabtagene autoleucel is usual care or a partner of the new treatment

Codes

What other systems call ciltacabtagene autoleucel · ClinicalTrials.gg INT014205

  • UNII (FDA) 0L1F17908QCILTACABTAGENE AUTOLEUCELOne source FDA
  • RxNorm 2594775One source FDA
  • NCI Thesaurus C148498Ciltacabtagene AutoleucelOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.